Navigation Links
WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
Date:7/11/2008

SHANGHAI, China, July 11 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has won the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. The Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology is awarded to the company that has demonstrated commendable success in forming strategic partnerships with global clients for outsourced laboratory and research manufacturing services in drug discovery and development in pharmaceuticals and biotechnology.

Quality of scientists and personnel, service portfolio, quality of services, speed of service delivery, cost competitiveness, past experience and referrals are the selection criteria that Frost & Sullivan used. According to Frost & Sullivan, WuXi has excelled in the delivery of high-quality services in a timely manner and at competitive costs through a team of proficient scientists supported by world-class management.

"Until January, 2008, WuXi PharmaTech had provided services to more than 700 global clients, with coverage of pharmaceutical, biotechnology and medical devices. High proportion of repeat and referral customers is a testament to its focus on customer satisfaction and operation excellence," said Frost & Sullivan Leader of China Healthcare Operation Mr. Xuchao Hou. "The main contributing factors to this impressive reward have been exceptional leverage of China's advantage, high technical expertise and world class management, robust expanding service portfolio, adherence to strict quality control and commitment to intellectual property rights protection."

"We are honored to receive this prestigious award in recognition of our research driven, customer focus and continuous improvement practices in helping our customers to improve the success of research and shorten the time of development," commented Dr. Ge Li. "We will continue expanding our service capabilities and capacity to better serve our global pharmaceutical and medical device customers."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

About Frost & Sullivan

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1,000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
2. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
3. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
4. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
5. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
6. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
7. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
11. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016  Eisai Inc. announced today final ... of rufinamide, which were presented at the 2016 ... held from December 2-6 in Houston, ... tolerability and cognitive data showed that patients who ... and tolerability profiles, cognitive development and behavior, compared ...
(Date:12/4/2016)... ... 02, 2016 , ... A proposed five-year extension for programs ... research and development is welcome news for the photonics community, say leaders of ... part of the National Defense Authorization Act (NDAA) compromise agreement finalized today between ...
(Date:12/4/2016)... CAMBRIDGE, Mass. and ... 4, 2016 SystemOne, a company focused ... platforms for the developing world, and Daktari Diagnostics, ... reality with its portable and ultrasensitive immunoassay-based CarePlatform™, ... development and license agreement to integrate Daktari,s technology ...
(Date:12/2/2016)... NORWALK, Conn. , Dec. 2, 2016  The ... research presentations from the MMRF CoMMpass Study SM —the ... and accelerating precision medicine in multiple myeloma—will be presented ... (ASH) Annual Meeting & Exposition in San ... are helping to optimize treatment strategies, as well as ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):